Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIFT-II: ABT-450/r/ABT-267 plus ribavirin in Japanese adults with genotype 2 chronic HCV
jRCT2080222382Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ombitasvir + paritaprevir + ritonavir and ribavirin in chronic hepatitis C (CHC), sponsored by AbbVie Inc.
02
Drugs
ombitasvir + paritaprevir + ritonavirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080222382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222382.